Modulation of paraoxonases during infectious diseases and its potential impact on atherosclerosis

Lipids in Health and Disease

Volumn 11, Issue , 2012, Pages

  Farid, Ayman Samir ^a,b   Horii, Yoichiro ^b  

^a Benha University   (Egypt)

^b UNIVERSITY OF MIYAZAKI   (Japan)

Author keywords

Atherosclerosis; Infectious diseases; Oxidative stress; Paraoxonases

Indexed keywords

ARYLDIALKYLPHOSPHATASE; ARYLDIALKYLPHOSPHATASE 1; ARYLDIALKYLPHOSPHATASE 2; ARYLDIALKYLPHOSPHATASE 3; UNCLASSIFIED DRUG;

ATHEROSCLEROSIS; BACTERIAL INFECTION; BACTERIAL VIRULENCE; CARDIOVASCULAR RISK; ENZYME ACTIVITY; GENE LOCUS; GENETIC POLYMORPHISM; HUMAN; INFECTION; INNATE IMMUNITY; LIPID OXIDATION; NONHUMAN; OXIDATIVE STRESS; PARASITOSIS; REVIEW; RISK REDUCTION; VIRUS INFECTION;

ANIMALS; ARYLDIALKYLPHOSPHATASE; ATHEROSCLEROSIS; BACTERIAL INFECTIONS; GENE EXPRESSION REGULATION; HUMANS; IMMUNITY, INNATE; PARASITIC DISEASES; VIRUS DISEASES;

BACTERIA (MICROORGANISMS); MUS;

EID: 84866663963     PISSN: None     EISSN: 1476511X     Source Type: Journal    
DOI: 10.1186/1476-511X-11-92     Document Type: Review

References (148)

1. The genetic mapping and gene structure of mouse paraoxonase/arylesterase. Sorenson RC, Primo-Parmo SL, Camper SA, La Du BN, Genomics 1995 30 431 438 10.1006/geno.1995.1261 8825627
2. The human serum paraoxonase/arylesterase gene (PON1) is one member of a multigene family. Primo-Parmo SL, Sorenson RC, Teiber J, La Du BN, Genomics 1996 33 498 507 10.1006/geno.1996.0225 8661009
3. Human PON3, effects beyond the HDL: clues from human PON3 transgenic mice. Draganov DI, Circ Res 2007 100 1104 1105 10.1161/01.RES.0000266976.89667. 31 17463324
4. Paraoxonase: biochemistry, genetics and relationship to plasma lipoproteins. Mackness MI, Mackness B, Durrington PN, Connelly PW, Hegele RA, Curr Opin Lipidol 1996 7 69 76 10.1097/00041433-199604000-00004 8743898
5. Paraoxonases 1, 2, and 3, oxidative stress, and macrophage foam cell formation during atherosclerosis development. Aviram M, Rosenblat M, Free Radic Biol Med 2004 37 1304 1316 10.1016/j.freeradbiomed.2004.06.030 15454271
6. Paraoxonase and coronary heart disease risk: language misleads, linkage misinforms, function clarifies. Loscalzo J, Circ Cardiovasc Genet 2008 1 79 80 10.1161/CIRCGENETICS.108.837179 20031548
7. Human paraoxonases (PON1, PON2, and PON3) are lactonases with overlapping and distinct substrate specificities. Draganov DI, Teiber JF, Speelman A, Osawa Y, Sunahara R, La Du BN, J Lipid Res 2005 46 1239 1247 10.1194/jlr.M400511- JLR200 15772423
8. Calcium-dependent human serum homocysteine thiolactone hydrolase. Jakubowski H, A protective mechanism against protein N-homocysteinylation. J Biol Chem 2000 275 3957 3962
9. Effects of B-vitamins on plasma homocysteine concentrations and on risk of cardiovascular disease and dementia. Clarke R, Lewington S, Sherliker P, Armitage J, Curr Opin Clin Nutr Metab Care 2007 10 32 39 10.1097/MCO. 0b013e328011aa71 17143052
10. The role of paraoxonase 1 in the detoxification of homocysteine thiolactone. Jakubowski H, Adv Exp Med Biol 2010 660 113 127 10.1007/978-1-60761-350-3-11 20221875
11. Paraoxonase 1 (PON1) is present in postprandial chylomicrons. Fuhrman B, Volkova N, Aviram M, Atherosclerosis 2005 180 55 61 10.1016/j.atherosclerosis. 2004.12.009 15823275
12. Protective effect of high density lipoprotein associated paraoxonase. Inhibition of the biological activity of minimally oxidized low density lipoprotein. Watson AD, Berliner JA, Hama SY, La Du BN, Faull KF, Fogelman AM, Navab M, J Clin Invest 1995 96 2882 2891 10.1172/JCI118359 8675659
13. Paraoxonase-1 inhibits oxidised LDL-induced MCP-1 production by endothelial cells. Mackness B, Hine D, Liu Y, Mastorikou M, Mackness M, Biochem Biophys Res Commun 2004 318 680 683 10.1016/j.bbrc.2004.04.056 15144891
14. Lipoproteins and the pathogenesis of atherosclerosis. Steinberg D, Carew TE, Fielding C, Fogelman AM, Mahley RW, Sniderman AD, Zilversmit DB, Circulation 1989 80 719 723 10.1161/01.CIR.80.3.719 2670321
15. Modified forms of low density lipoprotein and atherosclerosis. Aviram M, Atherosclerosis 1993 98 1 9 10.1016/0021-9150(93)90217-I 8457244
16. Role of oxidized low density lipoprotein in atherogenesis. Witztum JL, Steinberg D, J Clin Invest 1991 88 1785 1792 10.1172/JCI115499 1752940
17. Paraoxonase 1 (PON1) enhances HDL-mediated macrophage cholesterol efflux via the ABCA1 transporter in association with increased HDL binding to the cells: a possible role for lysophosphatidylcholine. Rosenblat M, Vaya J, Shih D, Aviram M, Atherosclerosis 2005 179 69 77 10.1016/j.atherosclerosis.2004.10.028 15721011
18. Paraoxonase (PON1) deficiency is associated with increased macrophage oxidative stress: studies in PON1-knockout mice. Rozenberg O, Rosenblat M, Coleman R, Shih DM, Aviram M, Free Radic Biol Med 2003 34 774 784 10.1016/S0891-5849(02)01429-6 12633754
19. Low serum paraoxonase: a risk factor for atherosclerotic disease? Mackness MI, Durrington PN, Ayub A, Mackness B, Chem Biol Interact 1999 119-120 389 397 22543014
20. Paraoxonase prevents accumulation of lipoperoxides in low-density lipoprotein. Mackness MI, Arrol S, Durrington PN, FEBS Lett 1991 286 152 154 10.1016/0014-5793(91)80962-3 1650712
21. HDL-associated paraoxonase-1 can redistribute to cell membranes and influence sensitivity to oxidative stress. Deakin SP, Bioletto S, Bochaton-Piallat ML, James RW, Free Radic Biol Med 2011 50 102 109 10.1016/j.freeradbiomed.2010.09.002 20850524
22. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Shih DM, Gu L, Xia YR, Navab M, Li WF, Hama S, Castellani LW, Furlong CE, Costa LG, Fogelman AM, Lusis AJ, Nature 1998 394 284 287 10.1038/28406 9685159
23. Combined serum paraoxonase knockout/apolipoprotein E knockout mice exhibit increased lipoprotein oxidation and atherosclerosis. Shih DM, Xia YR, Wang XP, Miller E, Castellani LW, Subbanagounder G, Cheroutre H, Faull KF, Berliner JA, Witztum JL, Lusis AJ, J Biol Chem 2000 275 17527 17535 10.1074/jbc.M910376199 10748217
24. Berrougui H, Loued S, Khalil A, Purified human paraoxonase-1 interacts with plasma membrane lipid rafts and mediates cholesterol efflux from macrophages Free Radic Biol Med 2012
25. Paraoxonase-1 deficiency in mice predisposes to vascular inflammation, oxidative stress, and thrombogenicity in the absence of hyperlipidemia. Ng DS, Chu T, Esposito B, Hui P, Connelly PW, Gross PL, Cardiovasc Pathol 2008 17 226 232 10.1016/j.carpath.2007.10.001 18402813
26. Paraoxonase 1 (PON1) deficiency in mice is associated with reduced expression of macrophage SR-BI and consequently the loss of HDL cytoprotection against apoptosis. Fuhrman B, Gantman A, Aviram M, Atherosclerosis 2010 211 61 68 10.1016/j.atherosclerosis.2010.01.025 20149374
27. Paraoxonase 1 (PON1) inhibits monocyte-to-macrophage differentiation. Rosenblat M, Volkova N, Ward J, Aviram M, Atherosclerosis 2011 219 49 56 10.1016/j.atherosclerosis.2011.06.054 21798540
28. Relationship of human paraoxonase-1 serum activity and genotype with atherosclerosis in individuals from the Deep South. Coombes RH, Crow JA, Dail MB, Chambers HW, Wills RW, Bertolet BD, Chambers JE, Pharmacogenet Genomics 2011 21 867 875 10.1097/FPC.0b013e32834cebc6 21960140
29. Paraoxonase-2 is a ubiquitously expressed protein with antioxidant properties and is capable of preventing cell-mediated oxidative modification of low density lipoprotein. Ng CJ, Wadleigh DJ, Gangopadhyay A, Hama S, Grijalva VR, Navab M, Fogelman AM, Reddy ST, J Biol Chem 2001 276 44444 44449 10.1074/jbc.M105660200 11579088
30. Mouse macrophage paraoxonase 2 activity is increased whereas cellular paraoxonase 3 activity is decreased under oxidative stress. Rosenblat M, Draganov D, Watson CE, Bisgaier CL, La Du BN, Aviram M, Arterioscler Thromb Vasc Biol 2003 23 468 474 10.1161/01.ATV.0000059385.95664.4D 12615656
31. Adenovirus mediated expression of human paraoxonase 2 protects against the development of atherosclerosis in apolipoprotein E-deficient mice. Ng CJ, Hama SY, Bourquard N, Navab M, Reddy ST, Mol Genet Metab 2006 89 368 373 10.1016/j.ymgme.2006.07.004 16935014
32. Paraoxonase-2 deficiency aggravates atherosclerosis in mice despite lower apolipoprotein-B-containing lipoproteins: anti-atherogenic role for paraoxonase-2. Ng CJ, Bourquard N, Grijalva V, Hama S, Shih DM, Navab M, Fogelman AM, Lusis AJ, Young S, Reddy ST, J Biol Chem 2006 281 29491 29500 10.1074/jbc.M605379200 16891303
33. Paraoxonase 2 (PON2) decreases high glucose-induced macrophage triglycerides (TG) accumulation, via inhibition of NADPH-oxidase and DGAT1 activity: studies in PON2-deficient mice. Meilin E, Aviram M, Hayek T, Atherosclerosis 2010 208 390 395 10.1016/j.atherosclerosis.2009.07.057 19748094
34. Paraoxonase 2 attenuates macrophage triglyceride accumulation via inhibition of diacylglycerol acyltransferase 1. Rosenblat M, Coleman R, Reddy ST, Aviram M, J Lipid Res 2009 50 870 879 19091699
35. Paraoxonases (PONs) 1, 2, and 3 are expressed in human and mouse gastrointestinal tract and in Caco-2 cell line: selective secretion of PON1 and PON2. Shamir R, Hartman C, Karry R, Pavlotzky E, Eliakim R, Lachter J, Suissa A, Aviram M, Free Radic Biol Med 2005 39 336 344 10.1016/j.freeradbiomed.2005.03. 016 15993332
36. Biological role, protein expression, subcellular localization, and oxidative stress response of paraoxonase 2 in the intestine of humans and rats. Levy E, Trudel K, Bendayan M, Seidman E, Delvin E, Elchebly M, Lavoie JC, Precourt LP, Amre D, Sinnett D, Am J Physiol Gastrointest Liver Physiol 2007 293 1252 G1261 10.1152/ajpgi.00369.2007 17916643
37. Rabbit serum paraoxonase 3 (PON3) is a high density lipoprotein- associated lactonase and protects low density lipoprotein against oxidation. Draganov DI, Stetson PL, Watson CE, Billecke SS, La Du BN, J Biol Chem 2000 275 33435 33442 10.1074/jbc.M004543200 10931838
38. Is it just paraoxonase 1 or are other members of the paraoxonase gene family implicated in atherosclerosis? Reddy ST, Devarajan A, Bourquard N, Shih D, Fogelman AM, Curr Opin Lipidol 2008 19 405 408 10.1097/MOL.0b013e328304b64e 18607188
39. Temporal and tissue-specific patterns of Pon3 expression in mouse: in situ hybridization analysis. Shih DM, Xia YR, Yu JM, Lusis AJ, Adv Exp Med Biol 2010 660 73 87 10.1007/978-1-60761-350-3-8 20221872
40. Human paraoxonase-3 is an HDL-associated enzyme with biological activity similar to paraoxonase-1 protein but is not regulated by oxidized lipids. Reddy ST, Wadleigh DJ, Grijalva V, Ng C, Hama S, Gangopadhyay A, Shih DM, Lusis AJ, Navab M, Fogelman AM, Arterioscler Thromb Vasc Biol 2001 21 542 547 10.1161/01.ATV.21.4.542 11304470
41. Adenovirus-mediated expression of human paraoxonase 3 protects against the progression of atherosclerosis in apolipoprotein E-deficient mice. Ng CJ, Bourquard N, Hama SY, Shih D, Grijalva VR, Navab M, Fogelman AM, Reddy ST, Arterioscler Thromb Vasc Biol 2007 27 1368 1374 10.1161/ATVBAHA.106.134189 17446441
42. Decreased obesity and atherosclerosis in human paraoxonase 3 transgenic mice. Shih DM, Xia YR, Wang XP, Wang SS, Bourquard N, Fogelman AM, Lusis AJ, Reddy ST, Circ Res 2007 100 1200 1207 10.1161/01.RES.0000264499.48737.69 17379834
43. A component of innate immunity prevents bacterial biofilm development. Singh PK, Parsek MR, Greenberg EP, Welsh MJ, Nature 2002 417 552 555 10.1038/417552a 12037568
44. Quorum sensing in bacteria. Miller MB, Bassler BL, Annu Rev Microbiol 2001 55 165 199 10.1146/annurev.micro.55.1.165 11544353
45. The pathogenesis of atherosclerosis: a perspective for the 1990s. Ross R, Nature 1993 362 801 809 10.1038/362801a0 8479518
46. Infection and atherosclerosis: emerging mechanistic paradigms. Epstein SE, Zhou YF, Zhu J, Circulation 1999 100 20 e28 10.1161/01.CIR.100.4.e20 10421626
47. Role of oxidative modifications in atherosclerosis. Stocker R, Keaney JF, Physiol Rev 2004 84 1381 1478 10.1152/physrev.00047.2003 15383655
48. Pathogens and atherosclerosis: Update on the potential contribution of multiple infectious organisms to the pathogenesis of atherosclerosis. Rosenfeld ME, Campbell LA, Thromb Haemost 2011 106 858 867 10.1160/TH11-06-0392 22012133
49. Inflammation and atherosclerosis. Libby P, Ridker PM, Maseri A, Circulation 2002 105 1135 1143 10.1161/hc0902.104353 11877368
50. Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes. Han CY, Chiba T, Campbell JS, Fausto N, Chaisson M, Orasanu G, Plutzky J, Chait A, Arterioscler Thromb Vasc Biol 2006 26 1806 1813 10.1161/01.ATV.0000227472.70734. ad 16709944
51. Expression of major HDL-associated antioxidant PON-1 is gender dependent and regulated during inflammation. Bin Ali A, Zhang Q, Lim YK, Fang D, Retnam L, Lim SK, Free Radic Biol Med 2003 34 824 829 10.1016/S0891-5849(02)01436-3 12654470
52. Human paraoxonase-1 gene expression by HepG2 cells is downregulated by interleukin-1beta and tumor necrosis factor-alpha, but is upregulated by interleukin-6. Kumon Y, Suehiro T, Ikeda Y, Hashimoto K, Life Sci 2003 73 2807 2815 10.1016/S0024-3205(03)00704-5 14511766
53. PON1 and oxidative stress in human sepsis and an animal model of sepsis. Draganov D, Teiber J, Watson C, Bisgaier C, Nemzek J, Remick D, Standiford T, La Du B, Adv Exp Med Biol 2010 660 89 97 10.1007/978-1-60761-350-3-9 20221873
54. Hynkova M, Zak A, Novakova O: Decreased paraoxonase activity in critically ill patients with sepsis. Novak F, Vavrova L, Kodydkova J, Novak F, Clin Exp Med 2010 10 21 25 10.1007/s10238-009-0059-8 19760042
55. Serum paraoxonase and arylesterase activities in patients with pulmonary tuberculosis. Naderi M, Hashemi M, Komijani-Bozchaloei F, Moazeni-Roodi A, Momenimoghaddam M, Pathophysiology 2011 18 117 120 10.1016/j.pathophys.2010.05. 002 21130618
56. Atherogenic changes of low-density lipoprotein susceptibility to oxidation, and antioxidant enzymes in pulmonary tuberculosis. Nezami N, Ghorbanihaghjo A, Rashtchizadeh N, Argani H, Tafrishinejad A, Ghorashi S, Hajhosseini B, Atherosclerosis 2011 217 268 273 10.1016/j.atherosclerosis.2011. 03.025 21497814
57. Serum paraoxonase-1 activity in Helicobacter pylori infected subjects. Aslan M, Nazligul Y, Horoz M, Bolukbas C, Bolukbas FF, Gur M, Celik H, Erel O, Atherosclerosis 2008 196 270 274 10.1016/j.atherosclerosis.2006.10.024 17125774
58. Chlamydia pneumoniae (TWAR). Kuo CC, Jackson LA, Campbell LA, Grayston JT, Clin Microbiol Rev 1995 8 451 461 8665464
59. Chlamydia pneumoniae-an infectious risk factor for atherosclerosis? Campbell LA, Kuo CC, Nat Rev Microbiol 2004 2 23 32 10.1038/nrmicro796 15035006
60. The acute phase reactant response to respiratory infection with Chlamydia pneumoniae: implications for the pathogenesis of atherosclerosis. Campbell LA, Yaraei K, Van Lenten B, Chait A, Blessing E, Kuo CC, Nosaka T, Ricks J, Rosenfeld ME, Microbes Infect 2010 12 598 606 10.1016/j.micinf.2010.04.001 20417302
61. Human and murine paraoxonase 1 are host modulators of Pseudomonas aeruginosa quorum-sensing. Ozer EA, Pezzulo A, Shih DM, Chun C, Furlong C, Lusis AJ, Greenberg EP, Zabner J, FEMS Microbiol Lett 2005 253 29 37 10.1016/j.femsle.2005.09.023 16260097
62. Structure-reactivity studies of serum paraoxonase PON1 suggest that its native activity is lactonase. Khersonsky O, Tawfik DS, Biochemistry (Mosc) 2005 44 6371 6382 10.1021/bi047440d
63. Paraoxonases as potential antibiofilm agents: their relationship with quorum-sensing signals in Gram-negative bacteria. Camps J, Pujol I, Ballester F, Joven J, Simo JM, Antimicrob Agents Chemother 2011 55 1325 1331 10.1128/AAC.01502-10 21199929
64. Effect of chronic Pseudomonas aeruginosa infection on the development of atherosclerosis in a rat model. Turkay C, Saba R, Sahin N, Altunbas H, Ozbudak O, Akkaya B, Ozbilim G, Colbasi I, Turkay M, Ogunc D, Bayezid O, Clin Microbiol Infect 2004 10 705 708 10.1111/j.1469-0691.2004.00920.x 15301672
65. The atherogenic effects of chlamydia are dependent on serum cholesterol and specific to Chlamydia pneumoniae. Hu H, Pierce GN, Zhong G, J Clin Invest 1999 103 747 753 10.1172/JCI4582 10074493
66. Inactivation of a Pseudomonas aeruginosa quorum-sensing signal by human airway epithelia. Chun CK, Ozer EA, Welsh MJ, Zabner J, Greenberg EP, Proc Natl Acad Sci U S A 2004 101 3587 3590 10.1073/pnas.0308750101 14970327
67. Paraoxonase-2 deficiency enhances Pseudomonas aeruginosa quorum sensing in murine tracheal epithelia. Stoltz DA, Ozer EA, Ng CJ, Yu JM, Reddy ST, Lusis AJ, Bourquard N, Parsek MR, Zabner J, Shih DM, Am J Physiol Lung Cell Mol Physiol 2007 292 852 L860 17122353
68. Paraoxonase-2 modulates stress response of endothelial cells to oxidized phospholipids and a bacterial quorum-sensing molecule. Kim JB, Xia YR, Romanoski CE, Lee S, Meng Y, Shi YS, Bourquard N, Gong KW, Port Z, Grijalva V, Reddy ST, Berliner JA, Lusis AJ, Shih DM, Arterioscler Thromb Vasc Biol 2011 31 2624 2633 10.1161/ATVBAHA.111.232827 21836061
69. Protective effect of paraoxonase-2 against endoplasmic reticulum stress-induced apoptosis is lost upon disturbance of calcium homoeostasis. Horke S, Witte I, Wilgenbus P, Altenhofer S, Kruger M, Li H, Forstermann U, Biochem J 2008 416 395 405 10.1042/BJ20080775 18691157
70. Paraoxonase 2 is down-regulated by the Pseudomonas aeruginosa quorumsensing signal N-(3-oxododecanoyl)-L-homoserine lactone and attenuates oxidative stress induced by pyocyanin. Horke S, Witte I, Altenhofer S, Wilgenbus P, Goldeck M, Forstermann U, Xiao J, Kramer GL, Haines DC, Chowdhary PK, Haley RW, Teiber JF, Biochem J 2010 426 73 83 10.1042/BJ20091414 19925453
71. Immunohistochemical analysis of paraoxonases-1, 2, and 3 expression in normal mouse tissues. Marsillach J, Mackness B, Mackness M, Riu F, Beltran R, Joven J, Camps J, Free Radic Biol Med 2008 45 146 157 10.1016/j.freeradbiomed. 2008.03.023 18440321
72. Atheroarteriosclerosis induced by infection with a herpesvirus. Minick CR, Fabricant CG, Fabricant J, Litrenta MM, Am J Pathol 1979 96 673 706 382868
73. Delivery of Chlamydia pneumoniae to the vessel wall aggravates atherosclerosis in LDLr/ mice. Hauer AD, de Vos P, Peterse N, ten Cate H, van Berkel TJ, Stassen FR, Kuiper J, Cardiovasc Res 2006 69 280 288 10.1016/j.cardiores.2005.07.011 16112098
74. Chlamydophila pneumoniae (Chlamydia pneumoniae) accelerates the formation of complex atherosclerotic lesions in Apo E3-Leiden mice. Ezzahiri R, Nelissen-Vrancken HJ, Kurvers HA, Stassen FR, Vliegen I, Grauls GE, van Pul MM, Kitslaar PJ, Bruggeman CA, Cardiovasc Res 2002 56 269 276 10.1016/S0008-6363(02) 00544-8 12393097
75. Paraoxonase activity in the serum and hepatic mRNA levels decrease during the acute phase response. Feingold KR, Memon RA, Moser AH, Grunfeld C, Atherosclerosis 1998 139 307 315 10.1016/S0021-9150(98)00084-7 9712337
76. High-density lipoprotein loses its anti-inflammatory properties during acute influenza a infection. Van Lenten BJ, Wagner AC, Nayak DP, Hama S, Navab M, Fogelman AM, Circulation 2001 103 2283 2288 10.1161/01.CIR.103.18.2283 11342478
77. Esmail Zahra LM: Oxidant and antioxidant of arylesterase and paraoxonase as biomarkers in patients with hepatitis C virus. Ali EM, Shehata HH, Ali-Labib R, Clin Biochem 2009 42 1394 1400 10.1016/j.clinbiochem.2009.06.007 19538950
78. Serum paraoxonase-3 concentration is associated with the severity of hepatic impairment in patients with chronic liver disease. García-Heredia A, Marsillach J, Aragonès G, Guardiola M, Rull A, Beltran- Dèbán R, Folch A, Mackness B, Mackness M, Pedro-Botet J, Joven J, Camps J, Clin Biochem 2011 44 1320 1324 10.1016/j.clinbiochem.2011.08.003 21854763
79. Maternal chronic hepatitis B virus is implicated with low neonatal paraoxonase/arylesterase activities. Schulpis KH, Barzeliotou A, Papadakis M, Rodolakis A, Antsaklis A, Papassotiriou I, Vlachos GD, Clin Biochem 2008 41 282 287 10.1016/j.clinbiochem.2007.10.013 18035058
80. Tekin Koruk S, Aksoy N: Serum paraoxonase and arylesterase activities in various forms of hepatitis B virus infection. Duygu F, J Clin Lab Anal 2011 25 311 316 10.1002/jcla.20473 21919063
81. Serum biomarkers of hepatitis B virus infected liver inflammation: a proteomic study. He QY, Lau GK, Zhou Y, Yuen ST, Lin MC, Kung HF, Chiu JF, Proteomics 2003 3 666 674 10.1002/pmic.200300394 12748946
82. Oxidation of specific methionine and tryptophan residues of apolipoprotein A-I in hepatocarcinogenesis. Fernández-Irigoyen J, Santamaría E, Sesma L, Mũoz J, Riezu JI, Caballeria J, Lu SC, Prieto J, Mato JM, Avila MA, Corrales FJ, Proteomics 2005 5 4964 4972 10.1002/pmic.200500070 16252306
83. HIV infection and high-density lipoprotein: the effect of the disease vs the effect of treatment. Rose H, Woolley I, Hoy J, Dart A, Bryant B, Mijch A, Sviridov D, Metabolism 2006 55 90 95 10.1016/j.metabol.2005.07.012 16324925
84. Serum paraoxonase-1 activity and concentration are influenced by human immunodeficiency virus infection. Parra S, Alonso-Villaverde C, Coll B, Ferré N, Marsillach J, Aragonès G, Mackness M, Mackness B, Masana L, Joven J, Camps J, Atherosclerosis 2007 194 175 181 10.1016/j.atherosclerosis. 2006.07.024 16942773
85. Putative innate immunity of antiatherogenic paraoxanase-2 via STAT5 signal transduction in HIV-1 infection of hematopoietic TF-1 cells and in SCID-hu mice. Yuan J, Devarajan A, Moya-Castro R, Zhang M, Evans S, Bourquard N, Dias P, Lacout C, Vainchenker W, Reddy ST, Koka PS, J Stem Cells 2010 5 43 48 20861927
86. Serum paraoxonase-3 concentration in HIV-infected patients. Aragonès G, García-Heredia A, Guardiola M, Rull A, Beltran-Dèbán R, Marsillach J, Alonso-Villaverde C, Mackness B, Mackness M, Pedro-Botet J, Pardo-Reche P, Joven J, Camps J, Evidence for a protective role against oxidation. J Lipid Res 2012 53 168 174
87. de Abreu Vieira PM, Arantes JM, Silva M, Pedrosa ML, Eloi-Santos SM, Martins-Filho OA, Teixeira-Carvalho A, Araújo MS, Tafuri WL, Carneiro CM: Increase of reactive oxygen species by desferrioxamine during experimental Chagas' disease. Francisco AF, Redox Rep 2010 15 185 190 10.1179/ 174329210X12650506623528 20663295
88. Cytokine production in hearts of Trypanosoma cruzi-infected CBA mice: Do cytokine patterns in chronic stage reflect the establishment of myocardial pathology? Sunnemark D, Ulfgren AK, rn A, Harris RA, Scand J Immunol 1996 44 421 429 10.1046/j.1365-3083.1996.d01-328.x 8947592
89. Silva Neto DT, Carvalho MR, Xu P, Serrano MG, Alves JM, Meirelles Mde N, Goldenberg S, Krieger MA, Buck GA: Trypanosoma cruzi infection induces a global host cell response in cardiomyocytes. Manque PA, Probst CM, Pereira MC, Rampazzo RC, Ozaki LS, Pavoni DP, Infect Immun 2011 79 1855 1862 10.1128/IAI.00643-10 21343357
90. Increased type 1 chemokine expression in experimental Chagas disease correlates with cardiac pathology in beagle dogs. Guedes PM, Veloso VM, Talvani A, Diniz LF, Caldas IS, Do-Valle-Matta MA, Santiago-Silva J, Chiari E, Galvao LM, Silva JS, Bahia MT, Vet Immunol Immunopathol 2010 138 106 113 10.1016/j.vetimm.2010.06.010 20619467
91. Are increased frequency of macrophage-like and natural killer (NK) cells, together with high levels of NKT and CD4+CD25high T cells balancing activated CD8+ T cells, the key to control Chagas' disease morbidity? Vitelli-Avelar DM, Sathler-Avelar R, Massara RL, Borges JD, Lage PS, Lana M, Teixeira-Carvalho A, Dias JC, Eloi-Santos SM, Martins-Filho OA, Clin Exp Immunol 2006 145 81 92 10.1111/j.1365-2249.2006.03123.x 16792677
92. Decreased serum paraoxonase-1 activity during intestinal nematode (Nippostrongylus brasiliensis) infection in rats. Farid AS, Nakahara K, Murakami N, Hayashi T, Horii Y, Am J Trop Med Hyg 2008 78 770 776 18458312
93. Intestinally implanted Nippostrongylus brasiliensis adult worms decrease serum paraoxonase-1 activity in rats. Farid AS, Shimohira T, Kobayashi I, Sawada J, Horii Y, Parasitol Int 2009 58 178 183 10.1016/j.parint.2009.03.001 19293000
94. An atherogenic lipid profile with low serum paraoxonase-1 activity during nematode infection in rats. Farid AS, Mido S, Linh BK, Hayashi T, Horii Y, Eur J Clin Invest 2010 40 984 993 10.1111/j.1365-2362.2010.02352.x 20695884
95. Trichinella spiralis: Infection changes serum paraoxonase-1 levels, lipid profile, and oxidative status in rats. Mido S, Fath EM, Farid AS, Nonaka N, Oku Y, Horii Y, Exp Parasitol 2012 131 190 194 10.1016/j.exppara.2012.03.023 22490818
96. Schistosoma mansoni: effect of dietary zinc supplement on egg granuloma in Swiss mice treated with praziqantel. Helmy MM, Mahmoud SS, Fahmy ZH, Exp Parasitol 2009 122 310 317 10.1016/j.exppara.2009.04.006 19389399
97. Ou JH: Mechanisms of liver injury. Choi J, III. Oxidative stress in the pathogenesis of hepatitis C virus. Am J Physiol Gastrointest Liver Physiol 2006 290 847 G851
98. Hepatitis C virus protein expression causes calcium-mediated mitochondrial bioenergetic dysfunction and nitro-oxidative stress. Piccoli C, Scrima R, Quarato G, D'Aprile A, Ripoli M, Lecce L, Boffoli D, Moradpour D, Capitanio N, Hepatology 2007 46 58 65 10.1002/hep.21679 17567832
99. Hepatitis C virus-induced oxidative stress suppresses hepcidin expression through increased histone deacetylase activity. Miura K, Taura K, Kodama Y, Schnabl B, Brenner DA, Hepatology 2008 48 1420 1429 10.1002/hep.22486 18671304
100. Cellular and molecular biology of HCV infection and hepatitis. Tang H, Grisè H, Clin Sci (Lond) 2009 117 49 65 10.1042/CS20080631
101. Hepatitis C virus, oxidative stress and steatosis: current status and perspectives. González-Gallego J, García-Mediavilla MV, Sánchez-Campos S, Curr Mol Med 2011 11 373 390 10.2174/156652411795976592 21568933
102. Hepatic paraoxonase activity alterations and free radical production in rats with experimental cirrhosis. Ferré N, Camps J, Cabre M, Paul A, Joven J, Metabolism 2001 50 997 1000 10.1053/meta.2001.25589 11555827
103. Paraoxonase status in coronary heart disease: are activity and concentration more important than genotype? Mackness B, Davies GK, Turkie W, Lee E, Roberts DH, Hill E, Roberts C, Durrington PN, Mackness MI, Arterioscler Thromb Vasc Biol 2001 21 1451 1457 10.1161/hq0901.094247 11557671
104. Genetic and environmental factors modulating serum concentrations and activities of the antioxidant enzyme paraoxonase-1. Deakin SP, James RW, Clin Sci (Lond) 2004 107 435 447 10.1042/CS20040187
105. Genetic association of paraoxonase-1 polymorphisms and chronic hepatitis C virus infection. Ferré N, Marsillach J, Camps J, Rull A, Coll B, Tous M, Joven J, Clin Chim Acta 2005 361 206 210 10.1016/j.cccn.2005.05.024 15993873
106. Human serum paraoxonases (PON1) Q and R selectively decrease lipid peroxides in human coronary and carotid atherosclerotic lesions: PON1 esterase and peroxidase-like activities. Aviram M, Hardak E, Vaya J, Mahmood S, Milo S, Hoffman A, Billicke S, Draganov D, Rosenblat M, Circulation 2000 101 2510 2517 10.1161/01.CIR.101.21.2510 10831526
107. High-density lipoprotein binding rate differs greatly between genotypes 1b and 2a/2b of hepatitis C virus. Kono Y, Hayashida K, Tanaka H, Ishibashi H, Harada M, J Med Virol 2003 70 42 48 10.1002/jmv.10372 12629642
108. The inverse association of serum HBV DNA level with HDL and adiponectin in chronic hepatitis B infection. Mohamadkhani A, Sayemiri K, Ghanbari R, Elahi E, Poustchi H, Montazeri G, Virol J 2010 7 228 10.1186/1743-422X-7-228 20840785
109. Epidemiological evidence for cardiovascular disease in HIV-infected patients and relationship to highly active antiretroviral therapy. Currier JS, Lundgren JD, Carr A, Klein D, Sabin CA, Sax PE, Schouten JT, Smieja M, Circulation 2008 118 29 e35 10.1161/CIRCULATIONAHA.107.189624 18566319
110. Soluble adhesion molecules and endothelial cell damage in HIV infected patients. Seigneur M, Constans J, Blann A, Renard M, Pellegrin JL, Amiral J, Boisseau M, Conri C, Thromb Haemost 1997 77 646 649 9134636
111. Effects of HIV infection and antiretroviral therapy on the heart and vasculature. Dubè MP, Lipshultz SE, Fichtenbaum CJ, Greenberg R, Schecter AD, Fisher SD, Circulation 2008 118 36 e40 10.1161/CIRCULATIONAHA.107.189625 18566318
112. Nevirapine increases high-density lipoprotein cholesterol concentration by stimulation of apolipoprotein A-I production. Franssen R, Sankatsing RR, Hassink E, Hutten B, Ackermans MT, Brinkman K, Oesterholt R, Arenas-Pinto A, Storfer SP, Kastelein JJ, Sauerwein HP, Reiss P, Stroes ES, Arterioscler Thromb Vasc Biol 2009 29 1336 1341 10.1161/ATVBAHA.109.192088 19667106
113. High affinity, stability, and lactonase activity of serum paraoxonase PON1 anchored on HDL with ApoA-I. Gaidukov L, Tawfik DS, Biochemistry (Mosc) 2005 44 11843 11854 10.1021/bi050862i
114. Effect of efavirenz on high-density lipoprotein antioxidant properties in HIV-infected patients. Pereira SA, Batuca JR, Caixas U, Branco T, Delgado-Alves J, Germano I, Lampreia F, Monteiro EC, Br J Clin Pharmacol 2009 68 891 897 10.1111/j.1365-2125.2009.03535.x 20002083
115. Human immunodeficiency virus-infection induces major changes in high-density lipoprotein particle size distribution and composition: the effect of antiretroviral treatment and disease severity. Aragonès G, Beltran-Dèbán R, Rull A, Rodríguez-Sanabria F, Fernández-Sender L, Camps J, Joven J, Alonso-Villaverde C, Clin Chem Lab Med 2010 48 1147 1152 20482383
116. Increased prevalence of subclinical coronary atherosclerosis detected by coronary computed tomography angiography in HIV-infected men. Lo J, Abbara S, Shturman L, Soni A, Wei J, Rocha-Filho JA, Nasir K, Grinspoon SK, AIDS 2010 24 243 253 10.1097/QAD.0b013e328333ea9e 19996940
117. Reactive oxygen species as universal constraints in life-history evolution. Dowling DK, Simmons LW, Proc Biol Sci 2009 276 1737 1745 10.1098/rspb.2008.1791 19324792
118. Parasitic infection and oxidative status are associated and vary with breeding activity in the Seychelles warbler. van de Crommenacker J, Richardson DS, Koltz AM, Hutchings K, Komdeur J, Proc Biol Sci 2012 279 1466 1476 10.1098/rspb.2011.1865 22048952
119. The LDL modification hypothesis of atherogenesis: an update. Steinberg D, J Lipid Res 2009 50 Suppl 376 S381 19011257
120. The immunoepidemiology of human hookworm infection. Quinnell RJ, Bethony J, Pritchard DI, Parasite Immunol 2004 26 443 454 10.1111/j.0141-9838.2004. 00727.x 15771680
121. Immune responses in hookworm infections. Loukas A, Prociv P, Clin Microbiol Rev 2001 14 689 703 table of contents 10.1128/CMR.14.4.689-703.2001 11585781
122. Chagas disease in a domestic transmission cycle, southern Texas, USA. Beard CB, Pye G, Steurer FJ, Rodriguez R, Campman R, Peterson AT, Ramsey J, Wirtz RA, Robinson LE, Emerg Infect Dis 2003 9 103 105 10.3201/eid0901.020217 12533289
123. Aortic endothelial cell changes in the acute septicemic phase of experimental Trypanosoma cruzi infection in rats: scanning and transmission electron microscopic study. Rossi MA, Am J Trop Med Hyg 1997 57 321 327 9311644
124. Asymptomatic coronary artery disease in chagasic patients with heart failure: prevalence and risk factors. Carvalho G, Rassi S, Bastos JM, Camara SS, Arq Bras Cardiol 2011 97 408 412 10.1590/S0066-782X2011005000103 22011801
125. Cellular and cytokine characterization of vascular inflammation in CBA/J mice chronically infected with Trypanosoma cruzi. Sunnemark D, Frostegard J, rn A, Harris RA, Scand J Immunol 1998 48 480 484 10.1046/j.1365-3083.1998.00410.x 9822255
126. Identification of novel diagnostic serum biomarkers for Chagas' disease in asymptomatic subjects by mass spectrometric profiling. Ndao M, Spithill TW, Caffrey R, Li H, Podust VN, Perichon R, Santamaria C, Ache A, Duncan M, Powell MR, Ward BJ, J Clin Microbiol 2010 48 1139 1149 10.1128/JCM.02207-09 20071547
127. Weatherly DB, Minning TA, Bundy B, Cavola C, Opperdoes FR, Orlando R, Tarleton RL: The Trypanosoma cruzi proteome. Atwood JA, Science 2005 309 473 476 10.1126/science.1110289 16020736
128. The importance of high-density lipoproteins for paraoxonase-1 secretion, stability, and activity. James RW, Deakin SP, Free Radic Biol Med 2004 37 1986 1994 10.1016/j.freeradbiomed.2004.08.012 15544917
129. Characterization of a novel trypanosome lytic factor from human serum. Raper J, Fung R, Ghiso J, Nussenzweig V, Tomlinson S, Infect Immun 1999 67 1910 1916 10085035
130. HDL particles as the trypanosome-killing factor in human serum: An exclusive or inconclusive role? Owen JS, Lorenz P, Betschart B, Parasitol Today 1996 12 250 251 15275208
131. Trypanosoma congolense: paraoxonase 1 prolongs survival of infected mice. Bhasin KK, Yu JM, Tward A, Shih D, Campbell DA, Lusis AJ, Exp Parasitol 2006 114 240 245 10.1016/j.exppara.2006.03.010 16682028
132. Anti-inflammatory properties of paraoxonase-1 in atherosclerosis. Mackness B, Mackness M, Adv Exp Med Biol 2010 660 143 151 10.1007/978-1-60761- 350-3-13 20221877
133. Signal sequence analysis of expressed sequence tags from the nematode Nippostrongylus brasiliensis and the evolution of secreted proteins in parasites. Harcus YM, Parkinson J, Fernández C, Daub J, Selkirk ME, Blaxter ML, Maizels RM, Genome Biol 2004 5 39 10.1186/gb-2004-5-6-r39 15186490
134. Paraoxonase 1 response to a high-fat diet: gender differences in the factors involved. Thoms-Moy E, Gianotti M, Proenza AM, Lladá I, Mol Med 2007 13 203 209 17592556
135. Enzymatic antioxidant systems in helminth parasites. Chiumiento L, Bruschi F, Parasitol Res 2009 105 593 603 10.1007/s00436-009-1483-0 19462181
136. Human serum paraoxonase (PON 1) is inactivated by oxidized low density lipoprotein and preserved by antioxidants. Aviram M, Rosenblat M, Billecke S, Erogul J, Sorenson R, Bisgaier CL, Newton RS, La Du B, Free Radic Biol Med 1999 26 892 904 10.1016/S0891-5849(98)00272-X 10232833
137. R OH, Chalfie M: The mechanosensory protein MEC-6 is a subunit of the C. elegans touch-cell degenerin channel. Chelur DS, Ernstrom GG, Goodman MB, Yao CA, Chen L, Nature 2002 420 669 673 10.1038/nature01205 12478294
138. An anti-atherogenic effect of Schistosoma mansoni infections in mice associated with a parasite-induced lowering of blood total cholesterol. Doenhoff MJ, Stanley RG, Griffiths K, Jackson CL, Parasitology 2002 125 415 421 12458825
139. Lipid metabolism in the parasitic and free-living flatworms, Schistosoma mansoni and Dugesia dorotocephala. Meyer F, Meyer H, Bueding E, Biochim Biophys Acta 1970 210 257 266 10.1016/0005-2760(70)90170-0 4319989
140. Specific binding of human low-density lipoprotein to the surface of schistosomula of Schistosoma mansoni and ingestion by the parasite. Bennett MW, Caulfield JP, Am J Pathol 1991 138 1173 1182 2024706
141. An evaluation of the marmoset Callithrix jacchus (sagüi) as an experimental model for the dyslipoproteinemia of human Schistosomiasis mansoni. Lima VL, Sena VL, Stewart B, Owen JS, Dolphin PJ, Biochim Biophys Acta 1998 1393 235 243 10.1016/S0005-2760(98)00076-9 9748601
142. Schistosoma mansoni infection reduces the incidence of murine cerebral malaria. Waknine-Grinberg JH, Gold D, Ohayon A, Flescher E, Heyfets A, Doenhoff MJ, Schramm G, Haas H, Golenser J, Malar J 2010 9 5 10.1186/1475-2875-9-5 20051114
143. Chronic exposure to schistosome eggs reduces serum cholesterol but has no effect on atherosclerotic lesion development. La Flamme AC, Harvie M, Kenwright D, Cameron K, Rawlence N, Low YS, McKenzie S, Parasite Immunol 2007 29 259 266 10.1111/j.1365-3024.2007.00942.x 17430549
144. Effects of Schistosoma mansoni worms and eggs on circulating cholesterol and liver lipids in mice. Stanley RG, Jackson CL, Griffiths K, Doenhoff MJ, Atherosclerosis 2009 207 131 138 10.1016/j.atherosclerosis.2009.04.037 19464685
145. New insights into immunological aspects of atherosclerosis. Jawien J, Pol Arch Med Wewn 2008 118 127 131 18476459
146. In vivo downregulation of T helper cell 1 immune responses reduces atherogenesis in apolipoprotein E-knockout mice. Laurat E, Poirier B, Tupin E, Caligiuri G, Hansson GK, Bariety J, Nicoletti A, Circulation 2001 104 197 202 10.1161/01.CIR.104.2.197 11447086
147. Low numbers of FOXP3 positive regulatory T cells are present in all developmental stages of human atherosclerotic lesions. de Boer OJ, van der Meer JJ, Teeling P, van der Loos CM, van der Wal AC, PLoS One 2007 2 779 10.1371/journal.pone.0000779 17712427
148. The role of interleukin-4 and interleukin-12 in the progression of atherosclerosis in apolipoprotein E-deficient mice. Davenport P, Tipping PG, Am J Pathol 2003 163 1117 1125 10.1016/S0002-9440(10)63471-2 12937153